LYPHF.US Luye Pharma Group Ltd

Healthcare Pharmaceuticals USA Stocks
0.2700 USD
Close of Nov 15, 2026
0.2041 0.3950
Market cap
USD 1.08B
P/E
27.0x
P/B
0.46x
ROE
9.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is LYPHF.US undervalued?

Graham number
Price0.2700
Graham value0.3622
Discount25.4%

LYPHF.US trades 25.4% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Luye Pharma Group Ltd fundamental analysis

No fundamental analysis for Luye Pharma Group Ltd yet.

Luye Pharma Group Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Luye Pharma Group Ltd

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. …

Full company profile